NewYork-Presbyterian cancer specialists are at the forefront of expanding and innovating treatment for everything from breast cancer to glioblastoma. In 2025, our physicians and researchers from Columbia and Weill Cornell Medicine improved progression-free survival for multiple types of cancer, employed artificial intelligence to inform clinical care, discovered biomarkers that predict treatment responses to help personalize care in complex cases, and more. These advancements are breaking ground for new solutions that can improve cancer outcomes for all patients.
Through two world-class cancer centers – Columbia’s NCI-designated Herbert Irving Comprehensive Cancer Center and Weill Cornell Medicine’s Meyer Cancer Center, our team of physician-scientists are transforming care for cancer patients across a broad spectrum of malignant diseases and conditions. From pursuing novel laboratory research to better predict, diagnose and treat cancer, to conducting clinical trials of promising new therapies, our physicians provide personalized treatment plans to deliver optimal outcomes.
Oncology (Cancer)
Featured Updates
On this episode of Advances in Care, Erin Welsh is joined by Dr. Lawrence Lustig, chair of the Department of Otolaryngology – Head & Neck Surgery at NewYork-Presbyterian and Columbia. Dr. Lustig has spent decades working to advance various interventions to treat genetic hearing loss and after years of research his team was the first to show that gene therapies could be effective at reversing genetic hearing loss in mouse models and eventually, humans. In April 2026, the FDA approved the first ever gene therapy for genetic deafness based on the work pushed forward by Dr. Lustig.









